
Bayer Submits Darolutamide for Third FDA Approval
Bayer has announced the submission of a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for its oral androgen receptor inhibitor, darolutamide. The company is seeking approval for darolutamide in combination with androgen deprivation therapy…













